![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Departments of Pharmacology (E.Z.M., Y.K., E. A., E.S.L.) and Neurobiology (E.A.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Discovery of K+ channel modulators is limited by low-throughput capacity of existing K+ channel assays. To enable high-throughput screening for novel pharmacological modulators of K+ channels, we developed an assay based on growth of yeast that functionally expresses mammalian Kir2.1 channels. Screening of 10,000 small molecules from a combinatorial chemical library yielded 42 potential Kir2.1 inhibitors. One compound, 3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol, was confirmed to inhibit K+ channels in patch-clamp measurements in mammalian cells with EC50 values of 60 and 1 µM for Kir2.1 and Kv2.1 channels, respectively. Inhibition of Kv2.1 channels decreased in the presence of the external pore blocker tetraethylammonium (TEA) and depended on a residue required for extracellular TEA action, suggesting that the identified compound targets the external mouth of the channel. Furthermore, at the nontoxic concentration of 3 µM, the identified compound completely abolished in vitro neuronal apoptosis mediated by Kv2.1 channels. Therefore, yeast-based screening has identified a novel uncharged neuroprotective mammalian K+ channel inhibitor.
Address correspondence to: Dr. Elena Zaks-Makhina, Department of Pharmacology, University of Pittsburgh School of Medicine, E1306 BST, Pittsburgh PA 15261. E-mail: elm59{at}pitt.edu
This article has been cited by other articles:
|
|
 |
|
  J.-H. Lee, B.-H. Lee, S.-H. Choi, I.-S. Yoon, M. K. Pyo, T.-J. Shin, W.-S. Choi, Y. Lim, H. Rhim, K. H. Won, et al. Ginsenoside Rg3 Inhibits Human Kv1.4 Channel Currents by Interacting with the Lys531 Residue Mol. Pharmacol., March 1, 2008; 73(3): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Redman, K. He, K. A. Hartnett, B. S. Jefferson, L. Hu, P. A. Rosenberg, E. S. Levitan, and E. Aizenman Apoptotic surge of potassium currents is mediated by p38 phosphorylation of Kv2.1 PNAS, February 27, 2007; 104(9): 3568 - 3573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Salvador-Recatala, Y. Kim, E. Zaks-Makhina, and E. S. Levitan Voltage-Gated K+ Channel Block by Catechol Derivatives: Defining Nonselective and Selective Pharmacophores J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 758 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grishin, H. Li, E. S. Levitan, and E. Zaks-Makhina Identification of {gamma}-Aminobutyric Acid Receptor-interacting Factor 1 (TRAK2) as a Trafficking Factor for the K+ Channel Kir2.1 J. Biol. Chem., October 6, 2006; 281(40): 30104 - 30111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Friedmann, A. Shriki, E. R. Bennett, S. Golos, R. Diskin, I. Marbach, E. Bengal, and D. Engelberg JX401, A p38{alpha} Inhibitor Containing a 4-Benzylpiperidine Motif, Identified via a Novel Screening System in Yeast Mol. Pharmacol., October 1, 2006; 70(4): 1395 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grishin, H. Ford, J. Wang, H. Li, V. Salvador-Recatala, E. S. Levitan, and E. Zaks-Makhina Attenuation of apoptosis in enterocytes by blockade of potassium channels Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G815 - G821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Andalib, J. F. Consiglio, J. G. Trapani, and S. J. Korn The External TEA Binding Site and C-Type Inactivation in Voltage-Gated Potassium Channels Biophys. J., November 1, 2004; 87(5): 3148 - 3161. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
